Ruxolitinib, a JAK1/JAK2 Selective Inhibitor, Ameliorates Gastrointestinal and Cutaneous Pathogenesis in MHC-Mismatched Preclinical Models of Acute and Chronic Graft-Versus-Host Disease

被引：1

作者：

Huarte, Eduardo ^{[1
]}

Parker, Melissa ^{[1
]}

Juvekar, Ashish ^{[1
]}

Oliver, Julian ^{[1
]}

Yao, Wenqing ^{[1
]}

Smith, Paul ^{[1
]}

机构：

[1] Incyte Corp, Wilmington, DE USA

来源：

BLOOD | 2019年 / 134卷

关键词：

D O I：

10.1182/blood-2019-126749

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

5608

引用

页数：2

共 24 条

[1] Ruxolitinib, a JAK1/JAK2 Selective Inhibitor Is Highly Efficacious in Corticosteroid Untreated and Refractory MHC-Mismatched Mouse Model of Acute GvHD
Juvekar, Ashish
Ruggeri, Bruce
Condon, Sindy
Borkowski, Andrew
Huber, Reid
Smith, Paul
BLOOD, 2018, 132
[2] Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models
Huarte, Eduardo
Peel, Michael
Juvekar, Ashish
Dube, Philip
Sarah, Sarala
Stephens, Lynn
Stewart, Becky
Long, Brian
Czerniak, Philip
Oliver, Julian
Smith, Paul
IMMUNOTHERAPY, 2021, 13 (12) : 977 - 987
[3] Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease
Ryu, Da-Bin
Lim, Ji-Young
Kim, Tae-Woo
Shin, Seoho
Lee, Sung-Eun
Park, Gyeongsin
Min, Chang-Ki
EXPERIMENTAL HEMATOLOGY, 2021, 98 : 36 - +
[4] A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease
Schroeder, Mark A.
Khoury, H. Jean
Jagasia, Madan
Ali, Haris
Schiller, Gary J.
Staser, Karl
Choi, Jaebok
Gehrs, Leah
Arbushites, Michael C.
Yan, Ying
Langmuir, Peter
Srinivas, Nithya
Pratta, Michael
Perales, Miguel-Angel
Chen, Yi-Bin
Meyers, Gabrielle
DiPersio, John F.
BLOOD ADVANCES, 2020, 4 (08) : 1656 - 1669
[5] Itacitinib, a JAK1 Selective Inhibitor is highly efficacious in a MHC-mismatched mouse model of acute GvHD
Juvekar, Ashish
Ruggeri, Bruce
Condon, Sindy
Smith, Paul
Scherle, Peggy
Montgomery, Michael
Delaite, Patricia
Beal, Dominic
Borkowski, Andrew
BONE MARROW TRANSPLANTATION, 2018, 53 : 472 - 472
[6] Itacitinib, a JAK1 Selective Inhibitor Preserves Graft-Versus-Leukemia (GVL), Enhances Survival and Is Highly Efficacious in a MHC-Mismatched Mouse Model of Acute GvHD
Juvekar, Ashish
Ruggeri, Bruce
Condon, Sindy
Borkowski, Andrew
Huber, Reid
Smith, Paul
BLOOD, 2018, 132
[7] The Jak1/Jak2 Inhibitor Momelotinib Inhibits Alk2, Decreases Hepcidin Production and Ameliorates Anemia of Chronic Disease (ACD) in Rodents
Asshoff, Malte
Warr, Matthew
Haschka, David
Tymoszuk, Piotr
Petzer, Verena
Demetz, Egon
Maciejewski, Pat
Seifert, Markus
Nairz, Manfred
Posch, Wilfried
Fowles, Peter
Weiss, Guenter
Whitney, Andy
Theurl, Igor
BLOOD, 2015, 126 (23)
[8] JAK1/2 inhibitor ruxolitinib induce polymorphonuclear myeloid-derived suppressor cells mobilization and function via jak/stat and mapk/nf-κb dependent manner in protecting against acute graft-versus-host disease
Cao, Y.
Wang, J.
Xu, Y.
Jiang, E.
Han, M.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 219 - 219
[9] Inhibition of Jak1/Jak2 Is More Effective Than Inhibition of Jak3 in Protecting Mice From Acute Graft-Versus-Host Disease (aGvHD) by Significantly Decreasing Alloreactive CD4+T-Cells
Carniti, Cristiana
Gimondi, Silvia
Vaccaroli, Raffaella
Vendramin, Antonio
Bermema, Anisa
Radaelli, Enrico
Mariotti, Jacopo
Corradini, Paolo
BLOOD, 2012, 120 (21)
[10] JAK1/2 inhibitor ruxolitinib promotes the expansion and suppressive action of polymorphonuclear myeloid-derived suppressor cells via the JAK/STAT and ROS-MAPK/NF-κB signalling pathways in acute graft-versus-host disease
Cao, Yigeng
Wang, Jiali
Jiang, Shan
Lyu, Mengnan
Zhao, Fei
Liu, Jia
Wang, Mingyang
Pei, Xiaolei
Zhai, Weihua
Feng, Xiaoming
Feng, Sizhou
Han, Mingzhe
Xu, Yuanfu
Jiang, Erlie
CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2023, 12 (02)

← 1 2 3 →